Results 131 to 140 of about 28,321 (229)

Advances in polycythemia vera treatment with targeted therapies and clinical trials. [PDF]

Discov Oncol
Hassanien D, AlYafei RA, Metwally OH, Alremawi I, Al-Kaabi AK, Elahtem M, Al-Sayed T, Yassin MA.   +7 more
europepmc   +1 more source

Evaluating the feasibility of a network meta-analysis comparing treatment options in polycythemia vera. [PDF]

J Comp Eff Res
Walden P, Hummel N, Kopiec A, Maliszewska Z, Naslazi E.   +4 more
europepmc   +1 more source

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study. [PDF]

Ann Hematol
Barbui T, Thiele J, Alvarez-Larran A, Rambaldi A, Vannucchi AM, Tefferi A.   +5 more
europepmc   +1 more source

Washington University Medical Alumni Quarterly, July 1944 [PDF]

, 1944

core   +1 more source

Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study. [PDF]

Ann Hematol
Neumark N, Jalowiec KA, Tichelli A, Porret N, Njue L, Vrotniakaite-Bajerciene K, Prince-Eladnani R, Angelillo-Scherrer A, Meyer SC, Rovó A.   +9 more
europepmc   +1 more source

Cost-effectiveness analysis of ropeginterferon alfa-2b for the management of patients with polycythemia vera in Japan. [PDF]

Int J Hematol
Yamaguchi H, Sugimoto Y, Gotoh A, Ota S, Igari H, Murata T, Hanada K, Komatsu N, Kirito K.   +8 more
europepmc   +1 more source

Evaluating inflammatory markers in distinguishing polycythemia Vera from secondary polycythemia: a prospect for novel diagnostic marker. [PDF]

Ann Hematol
Khaksari MN, Oraei Sajjadi K, Arianmanesh F, Ayatollahi H, Boroumand-Noughabi S.   +4 more
europepmc   +1 more source

A Case of Perioperative Management of Tongue Cancer Polycythemia Vera. [PDF]

Yonago Acta Med
Watanabe S, Inamura M, Kodani I.
europepmc   +1 more source

Sequential Transformation of Polycythemia Vera to Myelofibrosis and KMT2A-Rearranged Acute Myeloid Leukemia Treated With Revumenib: A Rare Case of Clonal Evolution. [PDF]

Cureus
Ahmad CM, Kastle RA, Zargarian L, Sawalha Y, Dalia S.   +4 more
europepmc   +1 more source

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control. [PDF]

Ther Adv Hematol
Harrison CN, Kiladjian JJ, Hamer-Maansson JE, Naim A, Palandri F, Passamonti F.   +5 more
europepmc   +1 more source